Pancreatic Cancer Research

ResearcherAsan Medical CenterActive in the last 2 years

Sang Soo Lee

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-3785-2341; OpenAlex author ID A5100656057, A5143991201. Sources: ClinicalTrials.gov.

Their work

Papers
20 (first author 2, last author 0)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
53
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: 1 paper, 1 trial · 2017: 1 paper · 2018: 4 papers · 2019: 3 papers · 2020: 3 papers · 2021: none · 2022: 4 papers · 2023: 1 paper · 2024: 1 paper

Papers 20

  1. Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancrea… Co-author DOI 10.1016/j.pan.2024.02.004↗
  2. Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX. Co-author DOI 10.4143/crt.2022.409↗
  3. The impact of preoperative EUS-FNA for distal resectable pancreatic cancer: Is it really effective enough to take risks? Co-author DOI 10.1007/s00464-021-08627-3↗
  4. Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1177/17588359221097190↗
  5. Current status and future perspective of neoadjuvant therapy in locally advanced and borderline resectable pancreatic adenocarcinoma: a narrative review. First author DOI 10.21037/cco-21-166↗
  6. Stereotactic Body Radiation Therapy versus Concurrent Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Propensity Score-Matched Analysis. Co-author DOI 10.3390/cancers14051166↗
  7. Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biom… First author DOI 10.1038/s41416-020-0867-x↗
  8. FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma. Co-author DOI 10.1177/1758835920953294↗
  9. Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.4143/crt.2019.190↗
  10. Prediction of Recurrence With KRAS Mutational Burden Using Ultrasensitive Digital Polymerase Chain Reaction of Radial Resection Margin of Resected Pancreatic D… Co-author DOI 10.1097/mpa.0000000000001255↗
  11. Stereotactic body radiation therapy for locally advanced pancreatic cancer. Co-author DOI 10.1371/journal.pone.0214970↗
  12. Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Canc… Co-author DOI 10.3390/cancers11030278↗
  13. Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing. Co-author DOI 10.1007/s10637-017-0497-1↗
  14. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. Co-author DOI 10.1007/s10637-018-0598-5↗
  15. Prognosis of Pancreatic Cancer Patients with Synchronous or Metachronous Malignancies from Other Organs Is Better than Those with Pancreatic Cancer Only. Co-author DOI 10.4143/crt.2017.494↗
  16. Contrast-Enhanced Endoscopic Ultrasound for Differentially Diagnosing Autoimmune Pancreatitis and Pancreatic Cancer. Co-author DOI 10.5009/gnl17391↗
  17. Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen. Co-author DOI 10.18632/oncotarget.17940↗
  18. Initial experience of EUS-guided radiofrequency ablation of unresectable pancreatic cancer. Co-author DOI 10.1016/j.gie.2015.08.048↗
  19. Survival effect of tumor size and extrapancreatic extension in surgically resected pancreatic cancer: proposal for improved T classification. Co-author DOI 10.1016/j.humpath.2014.06.030↗
  20. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally a… Co-author DOI 10.1016/j.surg.2012.03.010↗

Trials 1

  1. A Study to Evaluate the Effectiveness and Safety of EUS-guided Transluminal Drainage With 'Niti-S SPAXUS Stent' Principal investigator NCT02730663↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tae Jun Song · 15 shared papers, 2016–2024 · strength 1.41
  2. Dae Wook Hwang · 14 shared papers, 2017–2024 · strength 1.40
  3. Changhoon Yoo · 14 shared papers, 2017–2024 · strength 1.40
  4. Do Hyun Park · 15 shared papers, 2012–2024 · strength 1.36
  5. Kyu‐pyo Kim · 14 shared papers, 2014–2024 · strength 1.36
  6. Jin‐hong Park · 14 shared papers, 2012–2024 · strength 1.34
  7. Song Cheol Kim · 15 shared papers, 2012–2024 · strength 1.28
  8. Ki Byung Song · 13 shared papers, 2014–2024 · strength 1.18
  9. Dong Wan Seo · 13 shared papers, 2012–2024 · strength 1.15
  10. Baek‐Yeol Ryoo · 12 shared papers, 2017–2024 · strength 1.14
  11. Myung‐Hwan Kim · 12 shared papers, 2012–2022 · strength 0.94
  12. Dongwook Oh · 8 shared papers, 2016–2024 · strength 0.91
  13. Woohyung Lee · 4 shared papers, 2020–2023 · strength 0.43
  14. Seung‐Mo Hong · 5 shared papers, 2014–2024 · strength 0.42
  15. Bong Jun Kwak · 3 shared papers, 2022–2024 · strength 0.42
  16. Dong‐Wan Seo · 4 shared papers, 2014–2022 · strength 0.31
  17. Yejong Park · 2 shared papers, 2023–2024 · strength 0.30
  18. Jaewon Hyung · 2 shared papers, 2020–2022 · strength 0.27
  19. So Heun Lee · 2 shared papers, 2022–2023 · strength 0.26
  20. Inhwan Hwang · 3 shared papers, 2018–2020 · strength 0.24
  21. Sang Hyun Shin · 4 shared papers, 2012–2019 · strength 0.23
  22. Jong Hoon Kim · 3 shared papers, 2012–2022 · strength 0.22
  23. Jinhong Jung · 2 shared papers, 2019–2022 · strength 0.20
  24. Hyehyun Jeong · 1 shared paper, 2024 · strength 0.16
  25. Inkeun Park · 1 shared paper, 2024 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.